Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

P ROGRESS WITH C HRONIC M YELOGENOUS L EUKEMIA : A Personal Perspective over Four Decades

P ROGRESS WITH C HRONIC M YELOGENOUS L EUKEMIA : A Personal Perspective over Four Decades ▪▪ Abstract Our understanding and treatment of chronic myelogenous leukemia (CML) has progressed since 1960 in parallel with work on cancer in general. CML provided the first evidence of a specific genetic change associated with a human cancer (the Philadelphia chromosome) and the clonal nature of these disorders. With improved cytogenetic and molecular techniques over subsequent decades, the specific genetic rearrangements of CML and many other tumors were defined and the complex mechanisms of carcinogenesis gradually unraveled. During this period, improved treatments for CML (chemotherapy, interferon, bone marrow transplantation) were implemented, and therapy targeted to the specific genetic change in the leukemic cells has recently been brought to promising clinical trials. Similar efforts are under way for other human cancers, and although the problem is enormously complex, there is real hope for major improvements in controlling these disorders. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Medicine Annual Reviews

P ROGRESS WITH C HRONIC M YELOGENOUS L EUKEMIA : A Personal Perspective over Four Decades

Annual Review of Medicine , Volume 53 (1) – Feb 1, 2002

Loading next page...
 
/lp/annual-reviews/p-rogress-with-c-hronic-m-yelogenous-l-eukemia-a-personal-perspective-kueyppn082

References (42)

Publisher
Annual Reviews
Copyright
Copyright © 2002 by Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0066-4219
eISSN
1545-326X
DOI
10.1146/annurev.med.53.082901.103519
pmid
11818460
Publisher site
See Article on Publisher Site

Abstract

▪▪ Abstract Our understanding and treatment of chronic myelogenous leukemia (CML) has progressed since 1960 in parallel with work on cancer in general. CML provided the first evidence of a specific genetic change associated with a human cancer (the Philadelphia chromosome) and the clonal nature of these disorders. With improved cytogenetic and molecular techniques over subsequent decades, the specific genetic rearrangements of CML and many other tumors were defined and the complex mechanisms of carcinogenesis gradually unraveled. During this period, improved treatments for CML (chemotherapy, interferon, bone marrow transplantation) were implemented, and therapy targeted to the specific genetic change in the leukemic cells has recently been brought to promising clinical trials. Similar efforts are under way for other human cancers, and although the problem is enormously complex, there is real hope for major improvements in controlling these disorders.

Journal

Annual Review of MedicineAnnual Reviews

Published: Feb 1, 2002

There are no references for this article.